Artificial Intelligence for Aging Research and Cancer Drug Development
12-06-2023“AI could enhance cancer care and lead to personalized treatment based on age, among other patient-specific characteristics.”
Listen to an audio version of this press release
BUFFALO, NY- December 6, 2023 – A new editorial paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 22, entitled, “Artificial intelligence for aging research in cancer drug development.”
Aging is a multifactorial and complex process associated with various diseases, including cancer. In light of the growing aging population, the need for effective cancer treatments is more significant than ever. Artificial intelligence (AI) is playing an increasingly crucial role in aging research and cancer drug development in revealing the critical drivers of outcomes among a wide range of intrinsic and extrinsic factors.
In recent years, the use of AI in aging research has been rapidly increasing, suggesting that AI-based analysis of healthcare data may enhance clinical care. In this new editorial, researchers Dorsa Shirini, Lawrence H. Schwartz and Laurent Dercle from Columbia University Medical Center provide an overview of the potential benefits as well as the technical caveats of adopting AI to help researchers identify new targets, develop more effective therapies, and accelerate the discovery process of drug development in the context of aging research.
“In this review, we discuss how we could leverage AI technologies to consider a patient’s unique aging profile and tailor cancer treatment more precisely to the individual. This approach would help optimize treatment outcomes, minimize treatment-related risks, and improve the overall quality of care for patients, considering the complex interplay between aging and cancer treatment response.”
Read the full paper: DOI: https://doi.org/10.18632/aging.204914
Corresponding Author: Laurent Dercle
Corresponding Email: ld2752@cumc.columbia.edu
Keywords: artificial intelligence, aging, cancer research
Sign up for free Altmetric alerts about this article: https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.https://doi.org/10.18632/aging.204914
About Aging-US:
Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.
Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Please visit our website at www.Aging-US.com and connect with us:
- X
- YouTube
- Spotify, Apple, SoundCloud, and available wherever you listen to podcasts
For media inquiries, please contact media@impactjournals.com.